GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
Cannabis Law Report
AUGUST 10, 2021
This authorisation for TSC, represents the fourth approved indication of a cannabis-based medicine in the UK for GW and underlines GW’s commitment to the UK and regulatory approved cannabis-based medicines. “We The safety profile observed was consistent with findings from previous studies, with no new safety risks identified.
Let's personalize your content